BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 7700077)

  • 1. Potent vitamin D3 analogs: their abilities to enhance transactivation and to bind to the vitamin D3 response element.
    Imai Y; Pike JW; Koeffler HP
    Leuk Res; 1995 Mar; 19(3):147-58. PubMed ID: 7700077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.
    Jung SJ; Lee YY; Pakkala S; de Vos S; Elstner E; Norman AW; Green J; Uskokovic M; Koeffler HP
    Leuk Res; 1994 Jun; 18(6):453-63. PubMed ID: 8207963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid hormone receptor does not heterodimerize with the vitamin D receptor but represses vitamin D receptor-mediated transactivation.
    Raval-Pandya M; Freedman LP; Li H; Christakos S
    Mol Endocrinol; 1998 Sep; 12(9):1367-79. PubMed ID: 9731705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
    Verlinden L; Verstuyf A; Quack M; Van Camp M; Van Etten E; De Clercq P; Vandewalle M; Carlberg C; Bouillon R
    J Bone Miner Res; 2001 Apr; 16(4):625-38. PubMed ID: 11315990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression.
    Sasaki H; Harada H; Handa Y; Morino H; Suzawa M; Shimpo E; Katsumata T; Masuhiro Y; Matsuda K; Ebihara K
    Biochemistry; 1995 Jan; 34(1):370-7. PubMed ID: 7819220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system.
    Zhao XY; Eccleshall TR; Krishnan AV; Gross C; Feldman D
    Mol Endocrinol; 1997 Mar; 11(3):366-78. PubMed ID: 9058382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of 1,25-dihydroxyvitamin D3 stimulated osteocalcin gene transcription by tumor necrosis factor-alpha: structural determinants within the vitamin D response element.
    Kuno H; Kurian SM; Hendy GN; White J; deLuca HF; Evans CO; Nanes MS
    Endocrinology; 1994 Jun; 134(6):2524-31. PubMed ID: 8194478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1 alpha,25-Dihydroxy-20-epi-vitamin D3: an extraordinarily potent inhibitor of leukemic cell growth in vitro.
    Elstner E; Lee YY; Hashiya M; Pakkala S; Binderup L; Norman AW; Okamura WH; Koeffler HP
    Blood; 1994 Sep; 84(6):1960-7. PubMed ID: 8080998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro binding of vitamin D receptor occupied by 24R,25-dihydroxyvitamin D3 to vitamin D responsive element of human osteocalcin gene.
    Uchida M; Ozonco K; Pike JW
    J Steroid Biochem Mol Biol; 1997 Feb; 60(3-4):181-7. PubMed ID: 9191975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Singly dehydroxylated A-ring analogues of 19-nor-1alpha,25-dihydroxyvitamin D3 and 19-nor-22-oxa-1alpha,25-dihydroxyvitamin D3: novel vitamin D3 analogues with potent transcriptional activity but extremely low affinity for vitamin D receptor.
    Okano T; Nakagawa K; Tsugawa N; Ozono K; Kubodera N; Osawa A; Terada M; Mikami K
    Biol Pharm Bull; 1998 Dec; 21(12):1300-5. PubMed ID: 9881643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone.
    Haussler MR; Jurutka PW; Hsieh JC; Thompson PD; Selznick SH; Haussler CA; Whitfield GK
    Bone; 1995 Aug; 17(2 Suppl):33S-38S. PubMed ID: 8579895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoid X receptors stimulate and 9-cis retinoic acid inhibits 1,25-dihydroxyvitamin D3-activated expression of the rat osteocalcin gene.
    MacDonald PN; Dowd DR; Nakajima S; Galligan MA; Reeder MC; Haussler CA; Ozato K; Haussler MR
    Mol Cell Biol; 1993 Sep; 13(9):5907-17. PubMed ID: 8395017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels.
    Pakkala S; de Vos S; Elstner E; Rude RK; Uskokovic M; Binderup L; Koeffler HP
    Leuk Res; 1995 Jan; 19(1):65-72. PubMed ID: 7837819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of HBL100 human breast epithelial cells to vitamin D action.
    Agadir A; Lazzaro G; Zheng Y; Zhang XK; Mehta R
    Carcinogenesis; 1999 Apr; 20(4):577-82. PubMed ID: 10223184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
    Kim S; Shevde NK; Pike JW
    J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25-dihydroxyvitamin D3.
    Cheskis B; Lemon BD; Uskokovic M; Lomedico PT; Freedman LP
    Mol Endocrinol; 1995 Dec; 9(12):1814-24. PubMed ID: 8614417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the 1,25-dihydroxyvitamin D3-induced increase in vitamin D receptor (VDR) levels and binding of VDR-retinoid X receptor (RXR) to a direct repeat (DR)-3 type response element by an RXR-specific ligand in human keratinocyte cultures.
    Jensen TJ; Henriksen LO; Sølvsten H; Kragballe K
    Biochem Pharmacol; 1998 Mar; 55(6):767-73. PubMed ID: 9586948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
    Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
    J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements.
    Staal A; Van Wijnen AJ; Desai RK; Pols HA; Birkenhäger JC; Deluca HF; Denhardt DT; Stein JL; Van Leeuwen JP; Stein GS; Lian JB
    Endocrinology; 1996 May; 137(5):2001-11. PubMed ID: 8612541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.